Show simple item record

dc.contributor.authorAglago, Elom K.
dc.contributor.authorSchalkwijk, Casper G.
dc.contributor.authorFreisling, Heinz
dc.contributor.authorFedirko, Veronika
dc.contributor.authorHughes, David J.
dc.contributor.authorJiao, Li
dc.contributor.authorDahm, Christina C.
dc.contributor.authorOlsen, Anja
dc.contributor.authorTjønneland, Anne
dc.contributor.authorKatzke, Verena
dc.contributor.authorJohnson, Theron
dc.contributor.authorSchulze, Matthias B.
dc.contributor.authorAleksandrova, Krasimira
dc.contributor.authorMasala, Giovanna
dc.contributor.authorSieri, Sabina
dc.contributor.authorSimeon, Vittorio
dc.contributor.authorTumino, Rosario
dc.contributor.authorMacciotta, Alessandra
dc.contributor.authorBueno-De-Mesquita, Bas
dc.contributor.authorSkeie, Guri
dc.contributor.authorGram, Inger Torhild
dc.contributor.authorSandanger, Torkjel M
dc.contributor.authorJakszyn, Paula
dc.contributor.authorSánchez, Maria-Jose
dc.contributor.authorAmiano, Pilar
dc.contributor.authorColorado-Yohar, Sandra
dc.contributor.authorBarricarte, Aurelio
dc.contributor.authorPerez-Cornago, Aurora
dc.contributor.authorMayén, Ana-Lucia
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorGunter, Marc J.
dc.contributor.authorHeath, Alicia K.
dc.contributor.authorJenab, Mazda
dc.date.accessioned2022-04-04T12:55:34Z
dc.date.available2022-04-04T12:55:34Z
dc.date.issued2021-03-29
dc.description.abstractAdvanced glycation end-products (AGEs) are a heterogeneous group of compounds formed by the non-enzymatic reaction between amino acids and reducing sugars, or dicarbonyls as intermediate compounds. Experimental studies suggest that AGEs may promote colorectal cancer, but prospective epidemiologic studies are inconclusive. We conducted a case–control study nested within a large European cohort. Plasma concentrations of three protein-bound AGEs—Nε-(carboxy-methyl)lysine (CML), Nε-(carboxy-ethyl)lysine (CEL) and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1)—were measured by ultra-performance liquid chromatography–tandem mass spectrometry in baseline samples collected from 1378 incident primary colorectal cancer cases and 1378 matched controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional logistic regression for colorectal cancer risk associated with CML, CEL, MG-H1, total AGEs, and [CEL+MG-H1: CML] and [CEL:MG-H1] ratios. Inverse colorectal cancer risk associations were observed for CML (OR comparing highest to lowest quintile, ORQ5 versus Q1 = 0.40, 95% CI: 0.27–0.59), MG-H1 (ORQ5 versus Q1 = 0.73, 95% CI: 0.53–1.00) and total AGEs (OR Q5 versus Q1 = 0.52, 95% CI: 0.37–0.73), whereas no association was observed for CEL. A higher [CEL+MG-H1: CML] ratio was associated with colorectal cancer risk (ORQ5 versus Q1 = 1.91, 95% CI: 1.31–2.79). The associations observed did not differ by sex, or by tumour anatomical sub-site. Although individual AGEs concentrations appear to be inversely associated with colorectal cancer risk, a higher ratio of methylglyoxal-derived AGEs versus those derived from glyoxal (calculated by [CEL+MG-H1: CML] ratio) showed a strong positive risk association. Further insight on the metabolism of AGEs and their dicarbonyls precursors, and their roles in colorectal cancer development is needed.en_US
dc.descriptionThis is a pre-copyedited, author-produced version of an article accepted for publication in Carcinogenesis following peer review. The version of record Aglago, Schalkwijk, Freisling, Fedirko, Hughes, Jiao, Dahm, Olsen, Tjønneland, Katzke, Johnson, Schulze, Aleksandrova, Masala, Sieri, Simeon, Tumino, Macciotta, Bueno-De-Mesquita, Skeie, Gram, Sandanger, Jakszyn, Sánchez, Amiano, Colorado-Yohar, Barricarte, Perez-Cornago, Mayén, Weiderpass, Gunter, Heath, Jenab. Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study. Carcinogenesis. 2021;42(5):705-713 is available online at: https://doi.org/10.1093/carcin/bgab026.en_US
dc.identifier.citationAglago, Schalkwijk, Freisling, Fedirko, Hughes, Jiao, Dahm, Olsen, Tjønneland, Katzke, Johnson, Schulze, Aleksandrova, Masala, Sieri, Simeon, Tumino, Macciotta, Bueno-De-Mesquita, Skeie, Gram, Sandanger, Jakszyn, Sánchez, Amiano, Colorado-Yohar, Barricarte, Perez-Cornago, Mayén, Weiderpass, Gunter, Heath, Jenab. Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study. Carcinogenesis. 2021;42(5):705-713en_US
dc.identifier.cristinIDFRIDAID 2006117
dc.identifier.doi10.1093/carcin/bgab026
dc.identifier.issn0143-3334
dc.identifier.issn1460-2180
dc.identifier.urihttps://hdl.handle.net/10037/24702
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.relation.journalCarcinogenesis
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titlePlasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC studyen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record